中国寄生虫学与寄生虫病杂志 ›› 1984, Vol. 2 ›› Issue (1): 28-31.

• • 上一篇    下一篇

咯萘啶等4种抗疟药对约氏鼠疟原虫配子体与孢子增殖的影响

邵葆若,叶秀玉,郑浩   

  1. 中国预防医学中心寄生虫病研究所
  • 收稿日期:2017-01-12 修回日期:2017-01-12 出版日期:1984-02-28 发布日期:2017-01-12

EFFECT OF PYRONARIDINE AND THREE OTHER ANTIMALARIALSON GAMETOCYTES AND SPOROGONY OFPLASMODIUM YOELII

  • Received:2017-01-12 Revised:2017-01-12 Online:1984-02-28 Published:2017-01-12

摘要: 感染约氏鼠疟原虫配子体的小鼠灌服咯萘啶1,200mg/kg(相当于LD_(50))后2或12小时,给斯氏按蚊吸血,不影响配子体在蚊内发育为卵囊及感染性子孢子。小鼠灌服氯喹600mg/kg(相当于LD_(50))后也未见影响配子体对斯氏按蚊的感染;灌服乙胺嘧啶10mg/kg,能阻断配子体发育为卵囊;灌服伯喹20mg/kg,卵囊的发育也受抑制。蚊吸入合配子体的血液后,喂给0.005%咯萘啶,不影响约氏鼠疟原虫在蚊体内发育为有感染性的子孢子;喂给0.01%咯萘啶时,蚊几乎全部中毒死亡,而残存蚊仍查见形态正常的卵囊。给蚊喂氯喹液的结果与咯萘啶的相仿,但0.01%不引起蚊死亡。蚊吸0.001%乙胺嘧啶即

关键词: 配子体, 鼠疟原虫, 咯萘啶, 孢子增殖, 原虫血症, 小鼠, 抗疟药, 约氏疟原虫, 卵囊数, 斯氏按蚊

Abstract: When P. yoelii gametocyte-carrying mice administered ig with pyronaridine 1,200 mg base/kg ( LD50) were fed 2 or 12 hours later to batches of Anopheles stephensi, no affection was observed on the development of oocyst and infective sporo-zoite in the mosquitoes. Similar result was obtained in mosquitoes fed on mice medicated with chloroquine 600 mg base/kg ( LDSO). However, the formation of oocyst was inhibited when the mosquitoes were fed on mice drugged ig with 20 mg base/kg of primaquine or a larger dose of pyrimetltiamihe (10 mg/kg). When 0.005% pyronaridine was fed to the mosquitoes after their engorgement of gametocyte-blood meal, no influence on gametocyte infectivity and sporogony was noted. With 0.01% pyronar ridine most mosquitoes died of intoxication, but normal oocyst could still be found in the survivors. The result in mosquitoes exposed to ehloroquine was similar, normal oocysts being detected. In contrast, the feeding of 0.001% pyrimethamine to mosquitoes led to complete suppression of sporogony. 0.01% primaquine caused the death of many mosquitoes, but oocysts could still be found in the remainders. Primaquine inhibited the infectivity of gametocytes to mosquitoes and oocyst formation at the concentration of 0.1%, no oocyst being detected in the few survivors.